Dyne therapeutics investors

Author: dayn

August undefined, 2024

WebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ... WebApr 11, 2024 · Finally, Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 425.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,582 shares of the company's stock valued at $122,000 after buying an additional 7,757 shares in the last quarter. Institutional investors own 85.50% of the company's stock. …

Dyne Therapeutics, Inc. (NASDAQ:DYN) Forecasted to Post …

WebMar 20, 2024 · About Dyne Therapeutics. ... Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 . WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449. ipic services

We

WebMar 23, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 … WebFeb 27, 2024 · The 86 rating InvestorsObserver gives to Dyne Therapeutics Inc stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, DYN’s 86 overall rating means the stock scores better than 86 percent of all stocks. WebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual … orangetheory fitness altrincham

Dyne Therapeutics to Present at Investor Conferences in …

Is Dyne Therapeutics Inc (DYN) Stock a Good Investment? AAII

WebMay 15, 2024 · May 14, 2024 8:16 PM ET Dyne Therapeutics, Inc. (DYN) SA Transcripts. 135.02K Follower s. The following slide deck was published by Dyne Therapeutics, Inc. … WebFeb 28, 2024 · Latest Dyne Therapeutics Inc Stock News. As of February 28, 2024, Dyne Therapeutics Inc had a $681.8 million market capitalization, putting it in the 59th percentile of companies in the Biotechnology & Medical Research industry. Dyne Therapeutics Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. ipic south barrington tickets orangetheory fitness athens ga

"WebMar 20, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 ... " - Dyne therapeutics investors

Dyne therapeutics investors

Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior …

WebMar 20, 2024 · However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release. Contacts: Investors Dyne Therapeutics … WebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on …

Did you know?

WebNov 2, 2024 · Dyne Therapeutics, Inc. WALTHAM, Mass., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life ... WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

WebMar 2, 2024 · Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights. March 2, 2024 . PDF Version ... Investors Amy Reilly … WebFeb 18, 2024 · Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Rating) - Oppenheimer issued their FY2024 earnings estimates for Dyne Therapeutics in a report released on Tuesday, February 14th.Oppenheimer analyst F. Brisebois expects that the company will earn ($3.17) per share for the year. Oppenheimer currently has a "Outperform" rating …

WebAug 29, 2024 · Investors: Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media: Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ... WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).

WebMar 21, 2024 · Information Security Analyst Co-Op. Dyne Therapeutics. Waltham, MA. Posted: March 16, 2024. Full-Time. Company Overview: Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary …

WebDyne Therapeutics to Present at Upcoming Investor Conferences. WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a … orangetheory fitness apple watchWebNX-13. NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen … orangetheory fitness back bayWebLandos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. … ipic south barrington theaterWebMar 26, 2024 · When Dyne Therapeutics last reported its balance sheet in December 2024, it had zero debt and cash worth US$256m. In the last year, its cash burn was US$157m. Therefore, from December 2024 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces … ipic standard seatingWebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business … ipic south street seaportWebSep 6, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ... orangetheory fitness barcelonaWebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... orangetheory fitness back bay boston